- Home
- AUUD vs ONCO Comparison
AUUD vs ONCO Comparison
Compare AUUD & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- ONCO
- Stock Information
- Founded
- AUUD 2012
- ONCO 2018
- Country
- AUUD United States
- ONCO United States
- Employees
- AUUD N/A
- ONCO N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- ONCO Health Care
- Exchange
- AUUD Nasdaq
- ONCO Nasdaq
- Market Cap
- AUUD 4.1M
- ONCO 4.3M
- IPO Year
- AUUD 2021
- ONCO 2022
- Fundamental
- Price
- AUUD $0.94
- ONCO $2.17
- Analyst Decision
- AUUD
- ONCO
- Analyst Count
- AUUD 0
- ONCO 0
- Target Price
- AUUD N/A
- ONCO N/A
- AVG Volume (30 Days)
- AUUD 71.0K
- ONCO 29.6K
- Earning Date
- AUUD 11-06-2025
- ONCO 11-13-2025
- Dividend Yield
- AUUD N/A
- ONCO N/A
- EPS Growth
- AUUD N/A
- ONCO N/A
- EPS
- AUUD N/A
- ONCO N/A
- Revenue
- AUUD N/A
- ONCO $1,223,751.00
- Revenue This Year
- AUUD N/A
- ONCO N/A
- Revenue Next Year
- AUUD N/A
- ONCO N/A
- P/E Ratio
- AUUD N/A
- ONCO N/A
- Revenue Growth
- AUUD N/A
- ONCO N/A
- 52 Week Low
- AUUD $0.84
- ONCO $2.10
- 52 Week High
- AUUD $14.60
- ONCO $179.35
- Technical
- Relative Strength Index (RSI)
- AUUD 29.89
- ONCO 38.17
- Support Level
- AUUD $0.84
- ONCO $2.17
- Resistance Level
- AUUD $1.10
- ONCO $2.35
- Average True Range (ATR)
- AUUD 0.08
- ONCO 0.20
- MACD
- AUUD 0.01
- ONCO -0.02
- Stochastic Oscillator
- AUUD 28.46
- ONCO 29.91
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.